A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors

  1. Lookup NU author(s)
  2. Professor Ruth Plummer
  3. Rebecca Perrett
  4. Professor Alan Calvert
Author(s)Plummer ER, Vidal L, Perrett RH, Shaw H, Pilkington M, Hanwell J, Temple G, Fong P, Amelsberg A, Calvert AH, de Bono J
Publication type Article
JournalClinical Cancer Research
Issue24 Part 2 Supplement S
ISSN (print)1078-0432
ISSN (electronic)1557-3265
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
NotesConference: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics Philadelphia, PA, 14-18 November 2005.
Actions    Link to this publication